Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

Cappellini MD, Sheth S, Taher A, Al-Samkari H, Antmen AB, Beneitez D, Cannas G, Coates T, Czapla L, Dahlin JL, Estepp JH, Feenstra E, Georgiev P, Gheuens S, Price GM, Glenthøj A, Musallam KM, Osman K, Porter JB, Shao H, Uhlig K, van Beers EJ, Viprakasit V, Kuo KHM, Kattamis A, ENERGIZE-T Investigators

Open source

DOI: 10.1016/s0140-6736(26)00874-3
Published: 2026 Sep 12
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-00874-3,
  title = {Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.},
  author = {Cappellini MD and Sheth S and Taher A and Al-Samkari H and Antmen AB and Beneitez D and Cannas G and Coates T and Czapla L and Dahlin JL and Estepp JH and Feenstra E and Georgiev P and Gheuens S and Price GM and Glenthøj A and Musallam KM and Osman K and Porter JB and Shao H and Uhlig K and van Beers EJ and Viprakasit V and Kuo KHM and Kattamis A and ENERGIZE-T Investigators},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)00874-3},
  url = {https://doi.org/10.1016/s0140-6736(26)00874-3}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
AU  - Cappellini MD
AU  - Sheth S
AU  - Taher A
AU  - Al-Samkari H
AU  - Antmen AB
AU  - Beneitez D
AU  - Cannas G
AU  - Coates T
AU  - Czapla L
AU  - Dahlin JL
AU  - Estepp JH
AU  - Feenstra E
AU  - Georgiev P
AU  - Gheuens S
AU  - Price GM
AU  - Glenthøj A
AU  - Musallam KM
AU  - Osman K
AU  - Porter JB
AU  - Shao H
AU  - Uhlig K
AU  - van Beers EJ
AU  - Viprakasit V
AU  - Kuo KHM
AU  - Kattamis A
AU  - ENERGIZE-T Investigators
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)00874-3
UR  - https://doi.org/10.1016/s0140-6736(26)00874-3
ER  -

APA

MD, C., S, S., A, T., H, A., AB, A., D, B., G, C., T, C., L, C., JL, D., JH, E., E, F., P, G., S, G., GM, P., A, G., KM, M., K, O., JB, P., H, S., K, U., EJ, V. B., V, V., KHM, K., A, K., & Investigators, E. (2026). Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)00874-3

Source records

pubmed · retrieved 2026-09-25T23:53:18.943Z